FDA approves Synribo for chronic myelogenous leukemia

Author(s):

On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here